Overview

• Orforglipron is Eli Lilly’s first oral GLP-1 receptor agonist for obesity, offering a daily pill alternative to injectable therapies such as Wegovy and Mounjaro.
• At the highest daily dose, Orforglipron recipients lost an average 12.4% of their body weight over 72 weeks compared with 0.9% in the placebo group.
• Common side effects included nausea, constipation, diarrhea and vomiting, mirroring the gastrointestinal profile observed with existing GLP-1 injectables.
• The drug’s progress comes after Pfizer halted its oral GLP-1 candidate Danuglipron over liver safety concerns, highlighting the challenges of developing safe oral obesity medications.
• Eli Lilly plans to submit its regulatory application by December 2025 and intends to position the pill as a convenient alternative to current injection-based weight-loss treatments.